Iovance Biotherapeutics Shares Surge Over 30% on Record Q2 Revenue

Iovance Biotherapeutics reported second‑quarter revenue of about $99.3 million, a 66% increase from a year earlier and well above analysts' $87.7 million estimate. The boost was driven primarily by U.S. sales of its flagship cell therapy Amtagvi for advanced melanoma, which generated roughly $91 million. The company said it is reviewing its full‑year 2026 revenue guidance upward. Following the earnings release, Iovance’s stock jumped 34% in morning trading.

The strong results placed Iovance among the day’s top biotech gainers. Creative Medical Technology Holdings saw its shares rise more than 70% after securing a U.S. patent for exosome‑based immunotherapy for Type 1 diabetes, while Braveheart Bio debuted on Nasdaq with a 65% first‑day gain. These moves highlight robust investor interest in emerging biotech therapies.